Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
Recruiting · NCT06735118 · Interventional (participants receive a specific treatment) · Lead sponsor: Yunnan Cancer Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- CT/B ultrasound showed no fatty liver
- No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia
- Received neoadjuvant/adjuvant chemotherapy
Exclusion criteria
- Missing follow-up information
- Liver lesions (metastases, hemangioma, etc.)
- Poor image quality
Where it is running
1 location listed.
- Yunnan Cancer Hospital - Kunming, Yunnan, China